Cantor Fitzgerald analyst Jennifer Kim named EyePoint as one of the firm’s top picks heading into 2H23 and made no change to its Overweight rating or $31 price target. The firm thinks management’s continued execution and recent clinical and competitive developments deserve greater attention ahead of key upcoming readouts, continues to believe that the peak sales opportunity for EYP-1901 is under-appreciated, and believes the risk/reward is favorable heading into DAVIO 2 data, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on EYPT:
- EyePoint initiated with a Buy at JonesResearch
- EyePoint Pharmaceuticals Completes Enrollment in Phase 2 PAVIA Clinical Trial of EYP-1901 in Non-Proliferative Diabetic Retinopathy
- EyePoint Pharmaceuticals to Present at the Jefferies Healthcare Conference
- Alimera Soars as it Snaps Up Rights for Yutiq from EyePoint Pharma
- EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)